SMS Pharmaceuticals マネジメント
マネジメント 基準チェック /24
SMS Pharmaceuticals' CEO is Ramesh Potluri, appointed in Aug 1990, has a tenure of 34.25 years. total yearly compensation is ₹36.88M, comprised of 81.4% salary and 18.6% bonuses, including company stock and options. directly owns 36.22% of the company’s shares, worth ₹9.06B. The average tenure of the management team and the board of directors is 5.5 years and 2.3 years respectively.
主要情報
Ramesh Potluri
最高経営責任者
₹36.9m
報酬総額
| CEO給与比率 | 81.4% |
| CEO在任期間 | 34.3yrs |
| CEOの所有権 | 36.2% |
| 経営陣の平均在職期間 | 5.5yrs |
| 取締役会の平均在任期間 | 2.3yrs |
経営陣の近況
SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24
Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23Recent updates
SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Sep 07SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be Increased To ₹0.40
Aug 22Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%
Aug 20SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Aug 08What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling You
Jul 04Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18
Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Meaningful Debt Burden
Dec 09CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹570m |
| Mar 31 2024 | ₹37m | ₹30m | ₹498m |
| Dec 31 2023 | n/a | n/a | ₹361m |
| Sep 30 2023 | n/a | n/a | ₹288m |
| Jun 30 2023 | n/a | n/a | ₹150m |
| Mar 31 2023 | ₹31m | ₹30m | -₹71m |
| Dec 31 2022 | n/a | n/a | -₹42m |
| Sep 30 2022 | n/a | n/a | ₹9m |
| Jun 30 2022 | n/a | n/a | ₹259m |
| Mar 31 2022 | ₹38m | ₹26m | ₹622m |
| Dec 31 2021 | n/a | n/a | ₹789m |
| Sep 30 2021 | n/a | n/a | ₹911m |
| Jun 30 2021 | n/a | n/a | ₹791m |
| Mar 31 2021 | ₹47m | ₹21m | ₹625m |
| Dec 31 2020 | n/a | n/a | ₹458m |
| Sep 30 2020 | n/a | n/a | ₹319m |
| Jun 30 2020 | n/a | n/a | ₹308m |
| Mar 31 2020 | ₹26m | ₹20m | ₹316m |
| Dec 31 2019 | n/a | n/a | ₹386m |
| Sep 30 2019 | n/a | n/a | ₹405m |
| Jun 30 2019 | n/a | n/a | ₹406m |
| Mar 31 2019 | ₹32m | ₹20m | ₹400m |
| Mar 31 2018 | ₹32m | ₹20m | ₹317m |
報酬と市場: Ramesh's total compensation ($USD438.48K) is above average for companies of similar size in the Indian market ($USD179.47K).
報酬と収益: Ramesh's compensation has been consistent with company performance over the past year.
CEO（最高経営責任者
Ramesh Potluri (66 yo)
34.3yrs
在職期間
₹36,875,000
報酬
Mr. Ramesh Babu Potluri has been the Chairman and Managing Director of SMS Pharmaceuticals Limited since August 30, 1990. Mr. Potluri has pioneered the vision of developing SMS in to one of the leading Pha...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman & MD | 34.3yrs | ₹36.88m | 36.22% ₹ 9.1b | |
| Chief Financial Officer | 7.2yrs | ₹2.37m | データなし | |
| Company Secretary & Compliance Officer | 2.8yrs | ₹1.53m | データなし | |
| Executive Director | 3.8yrs | ₹36.83m | 15.74% ₹ 3.9b | |
| Assistant General Manager of HR and Legal | no data | データなし | データなし | |
| Head of HRD and General Manager of Purchases | no data | データなし | データなし |
5.5yrs
平均在職期間
61yo
平均年齢
経験豊富な経営陣: SMSPHARMA's management team is seasoned and experienced (5.5 years average tenure).
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman & MD | 34.3yrs | ₹36.88m | 36.22% ₹ 9.1b | |
| Executive Director | 4.4yrs | ₹36.83m | 15.74% ₹ 3.9b | |
| Additional Non-Executive Non-Independent Director | less than a year | データなし | 2.58% ₹ 646.8m | |
| Non-Executive & Independent Director | 5.3yrs | ₹245.00k | データなし | |
| Non-Executive & Independent Director | 6.5yrs | ₹590.00k | 0.035% ₹ 8.9m | |
| Additional Non-Executive Independent Director | less than a year | データなし | データなし | |
| Non-Executive Non-Independent Director | less than a year | データなし | データなし | |
| Non-Executive Independent Director | less than a year | データなし | データなし |
2.3yrs
平均在職期間
62yo
平均年齢
経験豊富なボード: SMSPHARMA's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.